para home

Geroa Diagnostics is a biotechnological company whose mission is to improve the health, the life-quality and medical care of patients suffering from Alzheimer’s disease. We accomplish this mission by developing innovative technologies and tools and by discovering new biomarkers for the diagnosis and early prediction of Alzheimer´s Disease as well as for exploring new therapeutic strategies for this and other CNS diseases.

Founded in 2015, Geroa Diagnostics is formed by Eva Carro and Gorka Orive, two internationally known scientists and by Juan Carlos del Castillo, an international expert in managing and leading innovative private companies in virtually all fields of biotechnology. Our novel proprietary scientific biomarker addresses numerous unmet needs in Alzheimer’s disease and has the potential to positively impact patients’ lives as well as those of their families.

Geroa Diagnostics is a Basque company that received funding from the SPRI (Business development Agency from the Basque Government, Vitoria, Spain)



AD Diagnosis

The cross-sectional study included AD (n= 80); MCI (n= 44); PD (n= 59) patients and elderly non-demented controls (n= 91)(all recruited from Neurology service of the University Hospital 12 de Octubre (Madrid, Spain).

  •   The biomarker was significantly and specifically reduced in saliva from mild cognitive impairment (MCI) and AD patients compared to healthy control group.
  •   Our saliva biomarker was shown to correlate to AD progression and to cognitive decline according to the MMSE scale.
  •   Diagnostic validation study: Our salivary biomarker cut-off value perfectly classified all patients and all cognitively healthy subjects.





AD Screening

We used two independent “apparently healthy” nondemented individuals cohorts with 306 subjects. These “non- clinical” cohorts, which have not been evaluated by neurologists, provide a good representation of general population in which aMCI/AD is under diagnosed.

  •  From the 18 apparently healthy subjects with pathologic-low levels of saliva biomarker, a total of 14 (77.7%) have been diagnosed with aMCI/AD approximately 3.5 years later.
  •  No subjects with normal-high levels of saliva biomarker at that time have been diagnosed with aMCI/AD approximately 3.5 years later.
  •  Our salivary Biomarker is robust for screening the “general population” and identifying those underdiagnosed subjects with later stage pre-clinical AD or MCI.


para prognosis






About us

Gorka Orive
Associate Professor, PhD in Pharmacy

Full-time Associate Professor of Biopharmaceutics, Pharmacokinetics and Pharmaceutical Technology, University of the Basque Country, Spain.

Scientific Advisor of the Regenerative Medicine Laboratory at Biotechnology Institute ImasD (BTI), Vitoria, Spain.

Researcher at the Spanish Research Network CIBER-BBN.

200 international scientific publications, 35 book chapters, 3 books and 3 patents. H-index:34*

Received several scientific awards and member of different international scientific societies. Principal Researcher of 10 national scientific projects.

Scientific advisor of biotech and pharma companies (Bayer, Agreenvec, NsGene…)

*One of the highest at his age of 39

Eva Carro
PhD in Biology

Chief Research group, Neurodegenerative Disorders Group. Research Institute Hospital 12 de Octubre, Madrid, Spain (2011-).

Chief Research group, Biomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED) (2015-).

Postdoctoral investigator at Lab. Retrovirus et Transfert Genetique, CNRS URA, Institute Pasteur, Paris; Dep. Of BBB, Reed Neurology Center, UCLA, LA, USA & Dep. Of Molecular and Cellular Neuroendocrinology, Cajal Institute, CSIC, Madrid, Spain.

Received several scientific honors.

Principal Researcher of National and International scientific projects.

Juan Carlos del Castillo
Economics & Business Management

Entrepreneurial executive with 18 years of broad experience managing and leading both large research centers and innovative private companies in virtually all fields of biotechnology.

Since leaving 1999 the management of the National Center of Biotechnology of Spain, we can highlight:

Managing Director of Grupo Genetrix (till August 2015), a reference holding in the Spanish Biotechnology.

Genetrix has contributed to the development of the biotechnology in Spain, incorporating some of its most prominent companies. Two of them, are listed on markets such as Frankfurt or Brussels stock exchange.

Contact Us

Contact Us

Your Name (required)

Your Email (required)


Your Message